DOCSLIB.ORG

Final Eia/Emp Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Final Eia/Emp Report FINAL EIA/EMP REPORT ENVIRONMENTAL IMPACT ASSESSMENT AND ENVIRONMENTAL MANAGEMENT PLAN FOR Setup a new API manufacturing unit of 500 TPA AT Village- Bhagwanpur, Tehsil- Derabassi, District- SAS Nagar, State- Punjab. PROJECT AREA- 4.4 Ha. (Study Period - 1st March, 2018 to 31st March, 2018) MONITORING DONE BY M/S. VARDAN ENVIROLAB (NABL ACCREDITATIONT-TC-6299 (Valid till- 04/08/2019, MOEFCC No S.O. 1783 (E) Valid till-29/06/2020) [Project or Activity 5(f) as per EIA Notification dated 14th Sept., 2006 and amended from time to time, the proposed project falls under category “A” due to the presence of interstate boundary of Haryana and Punjab within 5km (i.e. 1.8 km) from the project site in ESE direction and the project site is located outside the notified industrial area] APPLICANT M/s. United Biotech Pvt. Ltd. ENVIRONMENT CONSULTANT VARDAN ENVIRONET (QCI/NABET ACCREDITED NO. NABET/EIA/1619/RA0037) DOCUMENT NO. 2018_VI_00003_FINAL EIA_ Rev.00 October-2018 FINAL REPORT - ENVIRONMENT IMPACT ASSESSMENT/EMP New API manufacturing unit by United Biotech Pvt. Ltd. at Village- Bhagwanpur, Tehsil- Derabassi, District- S.A.S Nagar, State- Punjab REVIEW AND REVISION HISTORY History of revisions of the present report: Table I: History of the Revisions Rev. Date Description Review-1 Review-2 Approval Rev.00 30.07.2018 Draft EIA /EMP Mr. M.K. Kapila Mr. S.K. Sharma Mr. R.S. Yadav Report - - - Document No. 2018_VI_00003 Table II: Record of Review Rev. Date Description Review-1 Review-2 Approval Rev.00 October, Final EIA /EMP Mr. M.K. Kapila Mr. S.K. Sharma Mr. R.S. Yadav 2018 Report - - - This Report has been prepared by Vardan EnviroNet on behalf of and for the use of the M/s United Biotech Pvt. Ltd. with due consideration and skill as per our general terms and conditions of business and terms of agreement with M/s United Biotech Pvt. Ltd. Document No. 2018_VI_00003_FINAL EIA Page | i QCI-NABET Scheme for accreditation of EIA Consultant Organisations/Version 3/June 2015 DECLARATION BY CONSULTANT NABET Annexure – VII Declaration by Experts contributing to the EIA of M/s United Biotech Pvt. Ltd. at Village- Bhagwanpur, Tehsil- Derabassi, District- S.A.S Nagar, State- Punjab. Declaration by Experts contributing to the EIA: I, hereby, certify that I was part of the EIA team in the following capacity that developed the above EIA. EIA Co-ordinator: Name : Mr. Mukesh kapila Signature : Period of involvement : February, 2018 – Till date Contact information : D-142, Sector-57, Sushant Lok-III, Golf Course Extension Road, Gurugram (Haryana), 122002. Contact no : 9899651342 Email : [email protected] Functional Area Experts (FAEs): S. Functional Name of the Involvement during Signature No. Areas expert/s March, 2018 – Till date 1. AP FAE : a) Identifying the sources of Mr. S. k Sharma Emissions and mitigation measures. b) Site-specific micro meteorology monitoring. c) Ambient Air Quality (AAQ) Monitoring Impact predictions and mitigations. d) Budget Allocation 2. WP FAE : a) selection of sampling Mr. S.K Sharma locations b) Ground water quality monitoring and assessment, impacts on water environment and mitigations. c) Identification, FAA: characterization of effluent and Avi Tomar treatments there of Water balance and conservation ii QCI-NABET Scheme for accreditation of EIA Consultant Organisations/Version 3/June 2015 DECLARATION BY CONSULTANT measures. 3. SHW FAE : a) Identification of haz, solid Mr. S. K. Sharma waste generation, and their disposal and mitigation measure. b) Recycling and disposal 4. SE FAE : a) Determination of Ms. Shilpa Mishra demographic profile including socio economy & livelihood b) Assessing the changes in socio economic pattern c) Budget Allocation 5. EB FAE : a) Biological environment status Dr. Niteesh Kumar in respect of terrestrial faun and aquatic eco system b) Impact on ecological environment 6. HG FAE : a) Ground water resource Mr. R.S.Yadav assessment b) Impact on ground water potential and mitigation measures for avoiding Ground water contamination. 7. AQ FAE : Mr. Asif Hussain a) Processing of site- specific micro-meteorological data b) Collection and use of inversion / mixing Height data for modeling. c) Air dispersion modeling for prediction of GLCS due to PM1o, S02 and Nox 8. NV FAE : a) Analysis of ambient noise Mr. Asif Hussain quality data b) Impact due to plant noise and abatement measures 9. LU FAE: a) Analysis of data related to Mr. Asif Hussain land use pattern Land use map development. c) Impact on land environment iii QCI-NABET Scheme for accreditation of EIA Consultant Organisations/Version 3/June 2015 DECLARATION BY CONSULTANT in respect to land form change 10. RH FAE: a) Identification of hazardous Mrs. Anuradha prone areas Sharma b) Environment risk evaluation c) On-site and Off-site emergency planning 11. SC FAE: a) Monitoring, analysis Mr. S. K. Sharma Characterization of soil. b) Assessment of impact on soil quality and mitigation measure. Declaration by the Head of the accredited consultant organization/ authorized person of M/s United Biotech Pvt. Ltd. at Village- Bhagwanpur, Tehsil- Derabassi, District- SAS Nagar, State- Punjab. I, R.S. Yadav, hereby, confirm that the above mentioned experts prepared the EIA of M/s United Biotech Pvt. Ltd. I also confirm that I shall be fully accountable for any misleading information mentioned in this statement. Name: R. S. Yadav Designation: Managing Director iv FINAL REPORT - ENVIRONMENT IMPACT ASSESSMENT/EMP New API manufacturing unit by United Biotech Pvt. Ltd at Village- Bhagwanpur, INDEX Tehsil- Derabassi, District- S.A.S Nagar, State- Punjab INDEX CHAPTERS TITLE PAGE NO. I. REVIEW AND REVISION HISTORY i II. NABET ANNEXURE ii III. TABLE OF CONTENT v IV. LIST OF ANNEXURES xii V. LIST OF TABLES xii VI. LIST OF FIGURES xv VII. ABBREVIATIONS xvi VIII. TOR LETTER xix IX. TOR COMPLIANCE xxviii LIST OF CONTENT CHAPTERS TITLE PAGE NO. 1.0 INTRODUCTION 1 - 7 1.1 PURPOSE OF THE REPORT 1 1.2 IDENTIFICATION OF PROJECT AND PROJECT PROPONENT 1 1.2.1 PROJECT DETAILS 1 1.2.2 PROJECT PROPONENT 1 1.3 BRIEF DESCRIPTION OF NATURE, SIZE, LOCATION OF THE PROJECT 1 1.4 IMPORTANCE TO THE COUNTRY AND REGION 5 1.5 SCOPE OF THE STUDY 5 1.6 GENERIC STRUCTURE OF FINAL EIA REPORT 5 1.7 LAWS APPLICABLE TO THIS PROJECT 7 2.0 PROJECT DESCRIPTION 8-28 2.1 TYPE OF PROJECT 8 2.2 NEED FOR THE PROJECT 8 2.3 LOCATION OF PROJECT (MAPS SHOWING GENERAL LOCATION, 8 SPECIFIC LOCATIONS, PROJECT BOUNDARY AND PROJECT SITE LAYOUT) 2.4 SIZE OR MAGNITUDE OF OPERATION 13 2.5 PROPOSED SCHEDULE FOR APPROVAL AND IMPLEMENTATION 20 2.6 TECHNOLOGY AND PROCESS DESCRIPTION 20 2.7 PROJECT DESCRIPTION 21 2.7.1 LAND USE 21 2.7.2 RAW MATERIALS AND SOURCE 21 2.7.3 MACHINERY DETAILS 21 2.7.4 MASS BALANCE 21 2.7.5 WATER REQUIREMENT 22 2.7.6 FUEL REQUIREMENT 24 Document No. 2018_VI_00003_FINAL EIA_Rev.00 Page | v (Index) FINAL REPORT - ENVIRONMENT IMPACT ASSESSMENT/EMP New API manufacturing unit by United Biotech Pvt. Ltd at Village- Bhagwanpur, INDEX Tehsil- Derabassi, District- S.A.S Nagar, State- Punjab 2.7.7 MANPOWER 24 2.7.8 POWER REQUIREMENT 25 2.7.9 PROJECT COST 26 2.7.10 STACK DETAILS 26 2.7.11 EFFLUENTS DETAILS 26 2.7.12 HAZARDOUS WASTE GENERATION AND ITS MANAGEMENT 27 2.8 DESCRIPTION OF MITIGATION MEASURE INCORPORATED IN TO 27 THE PROJECT TO MEET ENVIRONMENTAL STANDARD, ENVIRONMENTAL OPERATING CONDITIONS OR OTHER EIA REQUIREMENTS 2.8.1 AIR POLLUTION 27 2.8.2 WASTE WATER TREATMENT, RECYCLE AND UTILIZATION 27 2.8.3 NOISE POLLUTION AND CONTROL SYSTEM 28 2.8.4 PROCESS EMISSION POLLUTION 28 3.0 DESCRIPTION OF THE ENVIRONMENT 29-71 3.1 INTRODUCTION 29 3.2 STUDY AREA 29 3.3 STUDY PERIOD 29 3.3.1 COMPONENTS & METHODOLOGY 29 3.4 ESTABLISHMENT OF BASELINE FOR VALUED ENVIRONMENTAL 29 COMPONENTS, AS IDENTIFIED IN THE SCOPE 3.4.1 METEOROLOGICAL DATA 29 3.5 AIR QUALITY 31 3.5.1 ANALYTICAL TECHNIQUES FOR AIR QUALITY MONITORING 31 3.5.2 AIR QUALITY MONITORING 31 3.5.3 METHODOLOGY ADOPTED FOR THE STUDY 31 3.5.3.1 OBSERVATIONS 34 3.6 NOISE ENVIRONMENT 37 3.6.1 OBSERVATIONS 37 3.7 SOIL ENVIRONMENT 40 3.7.1 SOIL QUALITY 40 3.7.2 CRITERIA ADOPTED FOR SELECTION OF SAMPLING LOCATIONS 40 3.7.3 METHODOLOGY AND SAMPLING 40 3.7.4 SOIL SAMPLING LOCATIONS 40 3.7.5 OBSERVATIONS 44 3.8 WATER ENVIRONMENT 44 3.8.1 OBSERVATIONS 52 3.9 LAND USE 52 3.9.1 DATA USED 52 3.9.2 METHODOLOGY ADOPTED FOR THEMATIC DATA EXTRACTION 52 Document No. 2018_VI_00003_FINAL EIA_Rev.00 Page | vi (Index) FINAL REPORT - ENVIRONMENT IMPACT ASSESSMENT/EMP New API manufacturing unit by United Biotech Pvt. Ltd at Village- Bhagwanpur, INDEX Tehsil- Derabassi, District- S.A.S Nagar, State- Punjab FROM THE SATELLITE IMAGERIES 3.10 HYDROGEOLOGY REPORT 58 3.10.1 PHYSIOGRAPHY 58 3.10.2 GEOMORPHOLOGY AND SOIL 58 3.11 GEOLOGY 61 3.12 HYDROGEOLOGY 61 3.12.1 GROUND WATER RESOURCES 62 3.12.2 STATUS OF GROUND WATER DEVELOPMENT 62 3.13 TOPOGRAPHY 63 3.14 CLIMATE 63 3.15 SEISMICITY 64 3.15.1 FLOOD HAZARD ZONATION OF THE AREA 65 3.16 TRAFFIC STUDY 68 3.16.1 CONCLUSION 69 3.17 SOCIO-ECONOMIC ENVIRONMENT 71 3.18 BIOLOGICAL ENVIRONMENT 71 4.0 ANTICIPATED ENVIRONMENTAL IMPACT AND MITIGATION 72-104 MEASURES 4.1 INTRODUCTION 72 4.2 IMPACT IDENTIFICATION 72 4.2.1 IMPACT IDENTIFICATION MATRIX 72 4.2.1.1 IMPACT IDENTIFICATION MATRIX DURING CONSTRUCTION PHASE 72 4.2.1.2 IMPACT IDENTIFICATION MATRIX DURING OPERATION PHASE 73 4.2.2 ASSESSMENT OF SIGNIFICANCE OF IMPACTS (CRITERIA FOR 74 DETERMINING SIGNIFICANCE, ASSIGNING SIGNIFICANCE) & MITIGATION MEASURES 4.2.2.1 IMPACT ASSESSMENT MATRIX DURING CONSTRUCTION PHASE 75 4.2.2.2 IMPACT ASSESSMENT MATRIX DURING OPERATION PHASE 76 4.3 AMBIENT AIR QUALITY MODELING AERMOD DISPERSION MODEL 77 4.4 STACK DETAILS 81 4.5 MITIGATION MEASURES FOR IMPACTS ON ENVIRONMENT DURING 88 CONSTRUCTION PHASE 4.5.1 IMPACT AND MITIGATION MEASURES ON AIR ENVIRONMENT 88 4.5.2 IMPACT AND MITIGATION MEASURES ON WATER ENVIRONMENT 88 4.5.3 IMPACT AND MITIGATION MEASURES ON SOIL ENVIRONMENT 88 4.5.4 IMPACT AND MITIGATION MEASURES ON NOISE ENVIRONMENT 89 4.5.5 IMPACT AND MITIGATION MEASURES ON LAND COVER/ LAND USE 89 4.5.6 IMPACT AND MITIGATION MEASURES ON HYDROGEOLOGY 89 4.5.7 IMPACT SCORING AND MITIGATION MEASURES ON GEOLOGY 89 4.5.8 IMPACT AND MITIGATION MEASURES DUE TO SOLID/ HAZARDOUS 90 4.5.9 IMPACT AND MITIGATION MEASURES DUE TO RISK HAZARDOUS 90 Document No.
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • (Esi Scheme) Laxminagar, Ajmer Road, Jaipur-302006
    DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref. No. F434/ESI/Store/LabEmp/2017/5540 Dated:01/11/2017 E- Tender Document For “E- Tender forAnalysis of Drugs, Cotton, Gauzes, Bandage & Other items” For The Office of the Director cum Ex-officio Dy. Secretary, Medical & Health Services ESI Scheme Rajasthan, Laxmi Nagar, Ajmer Road, Jaipur & attached ESIS Institutions in Rajasthan ( for the period of two years from the date of award. ) ( Non-transferable ) Price of Tender Document Rs. 2000/- Last date & time of submission of Technical & Financial Bids is 11.12.17 at 1:30 pm Date & time of online opening of Technical Bid is 11.12.17 at 3:00 pm Visit Us At http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in, www.health.rajasthan.gov.in/esi Our Address: DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 1/71 DIRECTORATE, MEDICAL & HEALTH SERVICES, (E.S.I. SCHEME) LAXMINAGAR, AJMER ROAD, JAIPUR-302006 Tel/Fax 0141-2223572,www.health.rajasthan.gov.in/esi E-Mail [email protected],[email protected] Ref.No.F434/ESI/Store/LabEmp/2017/ 5540 Dated:01/11/2017 E-bids in two separate bids (Technical & Financial) for the Empanelment of Analytic Testing Laboratories For The Test and Analysis of drugs, cotton, bandage, gauze & other items. Brief Details of E-Tender Estimated Cost : Rs 50 lacs EMD (Bid Security)Rs 100000/- RISL processing fees Rs 1000/- Cost of the Tender Document Rs 2000/- Performance Security 5% of contract value Services Required:- The service of analysis of drugs, cotton, gauze, bandages & other items are required in the office of the Director cum Ex- officio Dy.
    [Show full text]
  • Pharmacological Treatment Options for Alcohol Use Disorder*
    Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2015;28:283-300 Editorial / Editoryal DOI: 10.5350/DAJPN20152804001 Pharmacological Treatment Cuneyt Evren1, Muge Bozkurt2 1Assoc. Prof. Dr., 2Psychiatrist, Bakirkoy Training and Options for Alcohol Use Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Disorder* Istanbul - Turkey Address reprint requests to / Yazışma adresi: Assoc. Prof. Dr. Cuneyt Evren, Bakirkoy Training and Research Hospital for Psychiatry, Neurology and Neurosurgery, Alcohol and Drug Research, Treatment and Training Center (AMATEM), Istanbul, Turkey Phone / Telefon: +90-212-409-1515/2111, Fax / Faks: +90-212-409-1590, E-mail address / Elektronik posta adresi: [email protected] *Abridged version of the “Therapeutic Guideline for Alcohol Use Disorder” prepared by the Working Group Therapeutic Guideline for Alcohol Use Disorder. PHARMACOLOGICAL TREATMENT assess information obtained from studies regarding OPTIONS FOR ALCOHOL USE DISORDER drug treatments used in clinical practice today, which are summarized in Table 1. However, when examining Alcohol Use Disorder (AUD) and other alcohol- study results for pharmacological treatments, we related health problems are a significant public health immediately have to remember that all of those issue all over the world. The World Health Organization (WHO) reports that each year 3.3 million people lose Table 1: Drugs used for the therapy of alcohol use their lives due to harmful alcohol use, with 5.9% of all disorder (AUD) deaths being related to alcohol consumption (1). It has Drugs for AUD approved in Turkey been estimated that in 2010, the economic burden of Disulfiram Naltrexone alcohol-related costs was 155.8 billion Euro, of which Acamprosate 60% were connected to alcohol addiction (2).
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Toxicological Profile for Carbon Tetrachloride
    CARBON TETRACHLORIDE 27 3. HEALTH EFFECTS 3.1 INTRODUCTION The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of carbon tetrachloride. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­ observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear.
    [Show full text]
  • Alcool Expertise Collective Alcool Effets Sur La Santé Effets Sur La Santé
    Expertise collective Alcool Expertise collective Alcool Effets sur la santé Effets sur la santé Les effets de l’alcool sur la santé font aujour- d’hui encore l’objet d’une importante recherche. Les travaux nous apprennent que ces effets dépendent non seulement des niveaux de consommation, mais également de la suscepti- bilité du consommateur et de ses modalités de consommation. Effets cardiovasculaires délé- tères ou bénéfiques, cancers, hépatopathies, atteintes des systèmes nerveux central ou péri- phérique, toutes les conséquences d’une consommation d’alcool ont été passées au crible dans le cadre de cette expertise collective de l’Inserm effectuée à la demande de la Cnamts, du CFES et de la Mildt. Comment traduire les données récentes en Effets sur la santé termes d’information et de messages de préven- tion ? Les conclusions de cette expertise invitent à adapter ces messages aux différentes popula- tions (jeunes, adultes, personnes âgées) et aux situations particulières (femmes enceintes, Alcool conduite automobile, professions à risque, situations sanitaires à risque…). Prix 180 FF € 27,44 Expertise collective ISBN 2-85598-797-0 ISSN 1264-1782 www.inserm.fr Cet ouvrage présente les travaux du groupe d’experts réunis par l’Inserm dans le cadre de la procédure d’expertise collective, pour répondre aux questions posées par le Comité français d’éducation pour la santé (CFES), la Caisse nationale d’assurance maladie des travailleurs salariés (Cnamts) et la Mission interministérielle de lutte contre la drogue et la toxicomanie (Mildt) concer- nant les effets de la consommation d’alcool sur la santé. Il s’appuie sur les données scientifiques disponibles en date du premier semes- tre 2001.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Metadoxine in the Treatment of Acute and Chronic Alcoholism: a Review
    INTERNATIONAL JOURNAL OF IMMUNOI'ATIIOLOGY AND I'IIARMACOLOGY Vol. 16, no. 3, 207·214 (2003) REVIEWARTICLE METADOXINE IN THE TREATMENT OF ACUTE AND CHRONIC ALCOHOLISM: A REVIEW G. ADDOLORATO, C. ANCONA, E. CAPRISTO and G. GASBARRINI Institute ofInternal Medicine, Catholic University ofRome, Italy Received February 27, 2003 - Accepted August 5, 2003 Alcohol abuse and alcoholism are responsible for a wide variety of medical problems. The pharmaco­ therapeutic aspect of alcoholism includes the use of drugs, with different actions and objectives. Among them, metadoxine seems to be of interest. Metadoxine is able to accelerate the elimination of alcohol from the blood and tissues, to help restore the functional structure of the liver and to relieve neuro-psychological disorders associated with alcohol intoxication. Metadoxine also seems to be safe; in more than 15 years of post-marketing surveillance only minor aspecific and reversible events were monitored in patients exposed to the treatment. In this review the preclinical and clinical results obtained using metadoxine in acute and chronic alcohol intoxication are reported. Alcoholism is a multifactorial disorder in which major contributing factors to road accidents, suicide biologic and genetic factor interact along withcultural and violent death in young adults (11). and social factors (1,2). Alcohol addiction represents The pharmaco-therapeutic aspect of alcoholism a social problem and a relatively common disease of includes the use of drugs, with different actions and western countries like Europe and the USA. From 20 objectives (12). Among them, metadoxine seems to to 40% of subjects admitted to hospitals have alcohol­ be of interest. The present review evaluates the related problems (3) and in elderly people alcohol­ pharmacology and the therapeutic use ofmetadoxine related disorders represent as frequent a reason for (figure I), a drug promoted for the treatment of acute hospitalization as myocardial infarction (4).
    [Show full text]
  • Orphan Drug Dummy File
    Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 1. Prevention of secondary carnitine deficiency in valproic acid toxicity 2. Treatment of secondary carnitine deficiency in Sigma-Tau levocarnitine Carnitor 11/15/1989 valproic acid toxicity Pharmaceuticals, Inc. 2 1. Treatment of graft versus host disease in patients receiving bone marrow transplantation 2. Prevention of graft versus host disease in patients receiving Pediatric thalidomide n/a 9/19/1988 bone marrow transplantation Pharmaceuticals, Inc. 3 A Diagnostic for the management Advanced Imaging Theranost 68 Ga RGD n/a 10/1/2014 of Moyamoya disease (MMD) Projects, LLC (AIP) 4 Cadila heat killed Mycobacterium w Pharmaceuticals immunomodulator Cadi Mw 9/3/2004 Active tuberculosis Limited, Inc. 5 Adjunct to cytokine therapy in the treatment of acute myeloid Histamine Ceplene 12/15/1999 leukemia. EpiCept Corporation 6 Adjunct to surgery in cases of rh-microplasmin, ocriplasmin Jetrea 3/16/2004 pediatric vitrectomy ThromboGenics Inc. 7 Adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or Ferring Laboratories, Somatostatin Zecnil 6/20/1988 pancreas. Inc. Page 1 of 377 Orphan Drug Designations and Approvals List as of 09‐01‐2016 Governs October 1, 2016 ‐ December 31, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with Allos Therapeutics, efaproxiral n/a 7/28/2004 breast cancer Inc.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Emergence Agitation After Intraoperative Neurolytic Celiac Plexus Block with Alcohol: a Case Report Huixuan Zhou, Yinbing Pan, Cunming Liu and Xiaodi Sun*
    Zhou et al. BMC Anesthesiol (2021) 21:204 https://doi.org/10.1186/s12871-021-01426-2 CASE REPORT Open Access Emergence agitation after intraoperative neurolytic celiac plexus block with alcohol: a case report Huixuan Zhou, Yinbing Pan, Cunming Liu and Xiaodi Sun* Abstract Background: Emergence agitation after general anesthesia may cause several undesirable events in the clinic during patient anesthesia recovery, and acute alcohol intoxication, while rare in surgery, is one of the risk factors. Case presentation: A 66-year-old male patient was found to have pancreatic tail neoplasm upon computed tomog- raphy (CT) examination. The surgeon planned to resect the pancreatic tail under general anesthesia. However, the surgeon found extensive tumor metastasis in the abdominal cavity, and thus performed a neurolytic celiac plexus block (NCPB) with 40 ml 95% ethyl alcohol and fnished the surgery in approximately 1 h. Twenty minutes later, the patient was extubated and developed signifcant emergence agitation in the postoperative care unit, characterized by restlessness, uncontrollable movements, confusion and disorientation. The patient was fushed and febrile with an alcohol smell in his breath and was unable to follow commands. Patient symptoms were suspected to be due to acute alcohol intoxication. Thus, the patient was given 40 mg of propofol intravenously. Following treatment, the patient recovered with less confusion and disorientation after approximately 10 min. After treatment with propofol twice more, he regained consciousness, was calm and cooperative, had no pain, and could obey instructions approxi- mately 1 h and 40 min following the last treatment. Following this treatment, the patient was transferred to the inpatient ward and felt well.
    [Show full text]
  • Och Beroendevård, 2006-123-21
    Faktaunderlag till Nationella riktlinjer för missbruks- och beroendevård Socialstyrelsen klassificerar sin utgivning i olika dokumenttyper. Detta är ett Underlag från experter. Det innebär att det bygger på vetenskap och/eller be- prövad erfarenhet. Författarna svarar själva för innehåll och slutsatser. Social- styrelsen drar inga egna slutsatser i dokumentet. Experternas sammanställning kan dock bli underlag för myndighetens ställningstaganden. Artikelnr: 006-3- Sättning: Per-Erik Engström Publicerad: www.socialstyrelsen.se, april 2006 Förord Ett förslag till Nationella riktlinjer för missbruks- och beroendevård skick- as ut på remiss till bl.a. kommuner och landsting den 5 april 2006. Doku- mentet kommer även att vara tillgängligt på Socialstyrelsens webbplats. Samtidigt kommer faktaunderlaget till dessa riktlinjer och som här pre- senteras att publiceras på samma sida. I faktaunderlaget har samtliga de kunskapsöversikter som riktlinjerna baseras på samlats. Det omfattande materialet har varit föremål för viss redigering och granskning av Socialstyrelsen, men författarna svarar dock ensamma för innehållet. Översikterna utgör slutresultatet av de beställningar som Socialstyrel- sen gjorde årsskiftet 2002–2003 till de fem expertgrupper som anlitats. Kunskapsöversikterna ska i princip omfatta kunskapsläget fram till och med våren 2004. Kunskapsproduktionen inom missbruksområdet är om- fattande, vilket aktualiserar behovet av återkommande revisioner av fak- taunderlaget. Socialstyrelsen har för avsikt att påbörja ett sådant arbete under 2007. Medverkande i de expertgrupper som deltagit i framtagandet av detta faktaunderlag redovisas på sidan 13 (övriga medverkande i arbetet redo- visas i ovan nämnda riktlinjedokument). Socialstyrelsen vill samtidigt varmt tacka samtliga experter för deras engagerade och viktiga insats. Kjell Asplund Generaldirektör Ola Arvidsson och Ulf Malmström 3 Innehåll Expertgruppernas sammansättning ������������������������������������������������������� 3 1.
    [Show full text]